You are here
Here you will find some links related to the subject Nocturia, Societies involved with this topic and other institutions related to the Resource Centre.
International Continence Society (ICS)
The International Continence Society is a registered charity with a global health focus which strives to improve the quality of life for people affected by urinary, bowel and pelvic floor disorders by advancing basic and clinical science through education, research, and advocacy.
The ICS annual meeting is one of the most valued dates in the Urological, gynaecological, physiotherapy and nursing calendar attracting in excess of 3,000 delegates from all corners of the globe.
Each year our meeting takes place at a different venue around the world. Two days of ICS Educational Courses and Workshops precede the Scientific Programme.
A public forum follows the main Scientific Meeting to promote continence issues in the region and focus on bringing local organisations and patients together with the world’s leading researchers and latest information on continence drugs, devices, surgery, care, products and evidence based medicine.
European Association of Urology (EAU)
For almost 40 years the EAU has addressed the most pressing issues of urological care in Europe, through its scientific and educational initiatives, as well as its publications. The EAU delivers training, stimulates research, organises exchanges and broadcasts information. EAU History books record the evolution of urology as a specialty, and the EAU Guidelines support urologists in their day-to-day practice. More than 16,000 professionals have joined the EAU and together we create and explore numerous opportunities for professional growth and knowledge-sharing.
Our mission: To raise the level of urological care throughout Europe and beyond.
The EAU represents the leading authority within Europe on urological practice, research and education. Over 16,000 medical professionals have joined its ranks and help to create forward-looking solutions for continuous improvement, professional growth and knowledge sharing. The EAU delivers training, stimulates research and broadcasts information. The EAU’s scientific publications encourage discussion and its expert recommendations guide urologists in their every-day practice.
Are you a practicing urologist, a resident, a researcher? Whatever your interests are, the EAU is here to meet your needs. You are invited to explore all facets of a dynamic professionally managed organisation representing Europe’s urological professionals.
European Urology, the official journal of the EAU, has been a prestigious urological forum for over 35 years, and is currently read by more than 20,000 urologists across the globe. With an recently released 2013 Impact Factor of 12.480, the journal has become the leading scientific publication in the field of urology & nephrology journals according to the ISI Thompson Journal Citation Reports.
To keep up with the rapidly evolving world of medicine, technology and surgical techniques, European Urology is constantly updating and innovating its features and layout in order to provide the best clinical guidance, research and education for urologists across Europe and the world.
Elsevier is the publisher of European Urology, the official journal of the European Association of Urology.
European Urology publishes peer-reviewed original articles and topical reviews on a wide range of urological problems. Topics such as oncology, impotence, infertility, pediatrics, lithiasis and endourology, as well as recent advances in techniques, instrumentation, surgery and pediatric urology provide readers with a complete guide to international developments in urology.
Sleep Medicine the official journal of the World Association of Sleep Medicine and International Pediatric Sleep Association, is an indispensible resource to the sleep medicine clinician. The journal focuses on the human aspects of sleep, integrating the various disciplines that are involved in sleep medicine: neurology, clinical neurophysiology, internal medicine (particularly pulmonology and cardiology), psychology, psychiatry, sleep technology, pediatrics, neurosurgery, otorhinolaryngology, and dentistry
Bedwetting Resource Centre
Bedwetting, or nocturnal enuresis, a frequent medical condition affecting children, adolescents, and adults, can cause significant secondary psychosocial and emotional impacts on the patient and his/her family.
When evaluating a child who wets the bed after the age of 5, an important first distinction is whether the bedwetting is accompanied by daytime symptoms (non-monosymptomatic nocturnal enuresis; NMNE) or not (monosymptomatic nocturnal enuresis; MNE).
While most cases of MNE/”isolated” bedwetting are familial, a specific gene remains to be identified. The pathophysiology of bedwetting is known, and consists of high arousal threshold combined with either an overactive night-time bladder or a very high level of night-time urine production (nocturnal polyuria; NP), or a combination of both.
Advance Prostate Cancer Resource Centre
Diagnosis and treatment of metastatic and castration resistant prostate cancer became more and more and complex due to the increasing knowledge and understanding of the underlying molecular events and the subsequently deducted innovative medical treatment.
Modern imaging studies in CRPC have become more selective and currently include positron emission tomography, whole body magnetic resonance imaging, immunoscintigraphy besides the traditional studies such as bone scans and computed tomography.
Until recently the management of metastatic prostate cancer was straightforward with primary and secondary androgen deprivation followed by docetaxel-based chemotherapy once castration resistant disease had developed. This quite simple approach has changed dramatically over the last 2-3 years. Abiraterone acetate, Enzalutamide, and Radium-223 represent new active drugs which have been shown to improve survival in the pre- and in the post docetaxel era. Current clinical trials even evaluate the role of Enzalutamide and Abiraterone acetate as primary hormonal therapeutic approach. Sipuleucel-T, tasquinimod, and ipilimumab have been shown to exert some immunomodulatory effects with a significant therapeutic response in metastatic castration resistant prostate cancer. Innovative cytotoxic drugs such as cabazitaxel and molecular targeted approaches provide novel sequencing options to improve the treatment for patients with metastatic castration resistant prostate cancer.
The treating urologists and oncologists are often overwhelmed by the many new developing aspects in diagnosis and treatment of castration resistant prostate cancer and might be overstrained to adequately assess the clinical relevance of the new developments.
With the new tool of the Prostate Cancer Resource Centre, it is our goal to offer an informative platform to the interested uro-oncologist with regard to the latest developments in the management of castration resistant prostate cancer. We will inform the community about the most recent publications and clinical trials, and we will have international specialists referring their appraisal and experience with the new substances.
Uro Onco Resource Centre
The European Association of Urology and Elsevier are proud to present URO ONCO, the new online educational platform for all healthcare professionals in uro-oncology.
URO ONCO provides up-to-date information on developments in the field of urological malignancies. With urological tumours presenting three of the ten most commonly found cancers, the need for up-to-date cancer management knowledge is essential for urologists. New developments in the field of prostate and kidney cancer have involved other specialties such as medical oncology and radiotherapy, making cancer management a truly multidisciplinary endeavor. URO ONCO will keep you informed on the latest clinical trial findings, meeting reports, and interviews with experts. Giving you the latest insight into the backgrounds of these trials and how you can implement the findings in your everyday practice. Presentations from recent meetings will be available on URO ONCO and each topic is selected by a team of expert editors. Additional resources are also provided, with links to publications and abstracts from other relevant materials.
URO ONCO connects you rapidly to the latest information about oncology in urology.
SIU (Société Internationale d’Urologie)
The Société Internationale d’Urologie was founded in Paris, in 1907, by Dr. Jean Casimir Félix-Guyon. In 1997, the SIU established permanent headquarters in Montreal, Canada.The Society’s mission is to enable urologists in all nations, through international cooperation in education and research, to apply the highest standards of urological care to their patients. The SIU strives to position itself as a major international platform for sustainable urological education and collaborative philanthropic activities aimed at improving urological care.
The main goals initially identified by the founders of the SIU are still valid today:
- to create and maintain the best possible conditions for communicating scientific information;
- to promote both formal and informal contacts between national urological societies;
- to foster cooperation between urologists from all parts of the world despite a differences in material conditions, professional concerns and political views.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries, that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).